Antonia, S. J., Gettinger, S. N., Goldman, J., Brahmer, J., Borghaei, H., Chow, L. Q., … Hellmann, M. D. (2016). ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol, 11(11S), S250–S251. https://doi.org/10.1016/j.jtho.2016.09.008

Antonia, Scott J., Scott N. Gettinger, Jonathan Goldman, Julie Brahmer, Hossein Borghaei, Laura Q. Chow, Neal E. Ready, et al. “ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.” J Thorac Oncol 11, no. 11S (November 2016): S250–51. https://doi.org/10.1016/j.jtho.2016.09.008.

Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, et al. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S250–1.

Antonia, Scott J., et al. “ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.” J Thorac Oncol, vol. 11, no. 11S, Nov. 2016, pp. S250–51. Pubmed, doi:10.1016/j.jtho.2016.09.008.

Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S250–S251.